82 related articles for article (PubMed ID: 1524945)
1. Growth hormone secretion in diffuse idiopathic skeletal hyperostosis.
Altomonte L; Zoli A; Mirone L; Marchese G; Scolieri P; Barini A; Magarò M
Ann Ital Med Int; 1992; 7(1):30-3. PubMed ID: 1524945
[TBL] [Abstract][Full Text] [Related]
2. Growth promoting peptides in osteoarthritis and diffuse idiopathic skeletal hyperostosis--insulin, insulin-like growth factor-I, growth hormone.
Denko CW; Boja B; Moskowitz RW
J Rheumatol; 1994 Sep; 21(9):1725-30. PubMed ID: 7799357
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism.
Díez JJ; Grande C; Méndez J; González-Gancedo P; Iglesias P
Clin Endocrinol (Oxf); 2006 Jul; 65(1):27-34. PubMed ID: 16817815
[TBL] [Abstract][Full Text] [Related]
4. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
Rosenfalck AM; Fisker S; Hilsted J; Dinesen B; Vølund A; Jørgensen JO; Christiansen JS; Madsbad S
Growth Horm IGF Res; 1999 Apr; 9(2):96-105. PubMed ID: 10373342
[TBL] [Abstract][Full Text] [Related]
5. Impaired insulin secretion and uptake in patients with diffuse idiopathic skeletal hyperostosis.
Eckertova M; Krskova K; Penesova A; Radikova Z; Zlnay D; Rovensky J; Zorad S
Endocr Regul; 2009 Oct; 43(4):149-55. PubMed ID: 19908933
[TBL] [Abstract][Full Text] [Related]
6. Marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis.
Littlejohn GO; Smythe HA
J Rheumatol; 1981; 8(6):965-8. PubMed ID: 7035664
[TBL] [Abstract][Full Text] [Related]
7. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin.
Guido M; Romualdi D; De Marinis L; Porcelli T; Giuliani M; Costantini B; Lanzone A
Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431
[TBL] [Abstract][Full Text] [Related]
8. Diffuse idiopathic skeletal hyperostosis in diabetes mellitus, impaired glucose tolerance and obesity.
Coaccioli S; Fatati G; Di Cato L; Marioli D; Patucchi E; Pizzuti C; Ponteggia M; Puxeddu A
Panminerva Med; 2000 Dec; 42(4):247-51. PubMed ID: 11294086
[TBL] [Abstract][Full Text] [Related]
9. The role of growth factors in degenerative joint disorders.
Moskowitz RW; Boja B; Denko CW
J Rheumatol Suppl; 1991 Feb; 27():147-8. PubMed ID: 2027117
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
11. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
12. [Diffuse idiopathic skeletal hyperostosis and its relation to metabolic parameters].
Pavelková A; Pavelka K
Vnitr Lek; 2006 May; 52(5):477-80. PubMed ID: 16771094
[TBL] [Abstract][Full Text] [Related]
13. Body mass index and blood glucose: correlations with serum insulin, growth hormone, and insulin-like growth factor-1 levels in patients with diffuse idiopathic skeletal hyperostosis (DISH).
Denko CW; Malemud CJ
Rheumatol Int; 2006 Feb; 26(4):292-7. PubMed ID: 15703952
[TBL] [Abstract][Full Text] [Related]
14. Studies of glucose intolerance in cirrhosis of the liver.
Shankar TP; Solomon SS; Duckworth WC; Himmelstein S; Gray S; Jerkins T; Bobal MA; Iyer RS
J Lab Clin Med; 1983 Oct; 102(4):459-69. PubMed ID: 6352838
[TBL] [Abstract][Full Text] [Related]
15. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
16. Intra-erythrocyte deposition of growth hormone in rheumatic diseases.
Denko CW; Boja B; Malemud CJ
Rheumatol Int; 2003 Jan; 23(1):11-4. PubMed ID: 12548436
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease.
Donaghy A; Ross R; Gimson A; Hughes SC; Holly J; Williams R
Hepatology; 1995 Mar; 21(3):680-8. PubMed ID: 7533122
[TBL] [Abstract][Full Text] [Related]
19. Effect of endogenous GH secretion during hyperthermic bath on glucose metabolism and insulin release in man.
Jurcovicová J; Vigas M; Palát M; Jezová D; Klimes I
Endocrinol Exp; 1980 Sep; 14(3):221-6. PubMed ID: 7002532
[TBL] [Abstract][Full Text] [Related]
20. Use of the oral glucose tolerance test to define remission in acromegaly.
Vierhapper H; Heinze G; Gessl A; Exner M; Bieglmayr C
Metabolism; 2003 Feb; 52(2):181-5. PubMed ID: 12601629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
